Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to $57.1 million.

  • ImmunityBio's Total Current Liabilities fell 627.62% to $57.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.1 million, marking a year-over-year decrease of 627.62%. This contributed to the annual value of $54.9 million for FY2024, which is 572.89% down from last year.
  • Per ImmunityBio's latest filing, its Total Current Liabilities stood at $57.1 million for Q3 2025, which was down 627.62% from $50.6 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Total Current Liabilities ranged from a high of $613.5 million in Q2 2023 and a low of $49.2 million during Q1 2025
  • Over the past 5 years, ImmunityBio's median Total Current Liabilities value was $70.8 million (recorded in 2022), while the average stood at $191.2 million.
  • In the last 5 years, ImmunityBio's Total Current Liabilities skyrocketed by 46052.08% in 2021 and then tumbled by 9048.42% in 2024.
  • ImmunityBio's Total Current Liabilities (Quarter) stood at $369.0 million in 2021, then skyrocketed by 35.74% to $500.9 million in 2022, then plummeted by 88.36% to $58.3 million in 2023, then fell by 5.73% to $54.9 million in 2024, then increased by 3.99% to $57.1 million in 2025.
  • Its last three reported values are $57.1 million in Q3 2025, $50.6 million for Q2 2025, and $49.2 million during Q1 2025.